Eleusis

Eleusis

Private Company
Public Company
Feature Partner
Subsidiary of
Clinical Trials, R&D
1
Recent News
No items found.
🇨🇦
Canadian Markets
🇺🇸
US Markets
🇪🇺 European Markets

About

Eleusis is a clinical stage life science company dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity.
Features
News
New Wave: Enters into Partnership with the University of West Indies, Mona, Jamaica for Medicinal Drug Discovery
News
Pure Extracts Advances Plans for the Processing of Functional Mushroom Formulations
News
Psyched Wellness Ltd. Adds Kevin Feeney to the Advisory Board
News
MindMed Announces $25 Million Bought Deal Public Offering
© 2020 Psychedelic Finance
Market Data copyright © 2020 QuoteMedia | Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges) | RT=Real-Time, EOD=End of Day, PD=Previous Day | Market Data powered by QuoteMedia | Terms of Use